UNSPSC 51111747: Ixabepilone

This classification denotes an epothilone b analogue with the molecular formula C27H42N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K27005NP0A, chemically known as 17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1s,3s,7s,10r,11s,12s,16r)- but generally known as ixabepilone, which bears US NIH Compound Identifier 6445540.

UNSPSC 51111747 Ixabepilone, a Commodity code, shows minimal alignment between its nominal scope—a specific chemotherapy agent—and the actual state and local procurement activity recently tagged under it. The recent opportunities record Naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products. None of these solicitations involve ixabepilone or chemotherapy procurement. The code appears to serve as a catch-all taxonomy placeholder for pharmaceutical and health-supply contracting rather than reflecting procurement of this specific oncology product. State and local issuing bodies tagged here include counties (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), cities (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance covering multiple states including Oregon). The geographic spread spans Florida, Texas, Minnesota, and Oregon based on recent activity.

Recent representative opportunities include Seminole County's IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (due July 26, 2023, through the county e-Procurement Portal); the City of Tampa's IFB for medical and first aid supplies totaling an estimated $700,000 for the Tampa Fire Department Rescue Division with a March 13, 2026 deadline and a Small Local Business Enterprise set-aside offering a 5 percent bid discount not to exceed $10,000; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026, seeking vendor capabilities in direct pharmacy contracting); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring NDC-specific product information and mandatory relationships with authorized wholesalers including AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson. The code's misalignment with ixabepilone-specific demand signals low relevance for firms focused on that product line.